RETROSPECTIVE ANALYSIS OF FOLLICULAR LYMPHOMA PATIENTS IN TRAKYA UNIVERSITY SCHOOL OF MEDICINE: A SINGLE CENTER EXPERIENCE

Year 2021, Volume: 8 Issue: 1, 28 - 31, 28.02.2021

Fatih Erkan Akay , Beliz Koçyiğit , Fevzi Oktay Şişman , Mert Yücel Ayrık , İpek Savaşır , Elif Cengiz , Ufuk Demirci , Hakkı Onur Kırkızlar

Abstract

Aims: To establish a dataset including demographic features, disease characteristics, and survival rate of follicular lymphoma patients in Trakya Universi- ty School of Medicine and contribute to the database of follicular lymphoma in Turkey. Methods: In this retrospective cross-sectional study, we analyzed data constituting of follicular lymphoma patients over 18 years of age followed during the years of 2015-2020 in Trakya University Division of Hematology. Results: Out of 43 patients, 22 (51.2%) were female and 21 (48.8%) were male. The mean age was 56.56 (standard deviation 13.24) years. There were 5 (11.6%) pa- tients with B symptoms, presence of bone marrow involvement was seen in 17 (39.5%) patients, lastly, there were 18 (41.9%) patients with splenomegaly. Twen- ty-one (48.8%) patients received rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, making it the most common treatment protocol administered in our study. Conclusion: Follicular lymphoma patients usually end up getting diagnosed at an advanced stage of the disease, presenting with incidentally noticed painless lymphadenopathy. Additionally, based on evidence in the literature, a clear gap in the successful diagnosis of follic- ular lymphoma patients can be observed between developed and developing countries. To overcome this hurdle, enhanced cooperation with hematopathology may lead to an increased awareness enabling physicians to make a more accurate diagnosis. Nonetheless, further studies are still needed to fully apprehend the epidemiology of follicular lymphoma patients in Turkey.

Keywords

Follicular lymphoma, retrospective study, non-Hodgkin’s lymphomas

References

• 1. Galaznik A, Huelin R, Stokes M et al. Systematic review of therapy used in re- lapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma. Fu- ture Sci OA 2018;4(7):322.
• 2. Swerdlow SH, Campo E, Pileri SA et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127(20):2375-90.
• 3. Dada R. Diagnosis and management of follicular lymphoma: a comprehensive review. Eur J Haematol 2019;103(3):152-63.
• 4. Project TN-HsLC. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89(11):3909-18.
• 5. Agopian J, Navarro JM, Gac AC et al. Agricultural pesticide exposure and the molecular connection to lymphomagenesis. J Exp Med 2009;206(7):1473-83.
• 6. Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol 2020;95(3):316-27.
• 7. Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. J Clin Invest 2012;122(10):3424-31.
• 8. Turkish Hematology Association. Lymphoma diagnosis and treatment guideline. 1.4th edition. Turkey; 2020.
• 9. Sugimoto T, Watanabe T. Follicular lymphoma: The role of the tumor microenvi- ronment in prognosis. J Clin Exp Hematop 2016;56(1):1-19.
• 10. Becnel MR, Nastoupil LJ. Follicular lymphoma: Past, present, and future. Curr Treat Options Oncol 2018;19(7):32.
• 11. Federico M, Vitolo U, Zinzani PL et al. Prognosis of follicular lymphoma: a predic- tive model based on a retrospective analysis of 987 cases. Blood 2000;95(3):783-9.
• 12. Kahraman S, Katgı A, Pişkin Ö et al. Tek merkez deneyimi: folliküler lenfomalı olgularımızın retrospektif değerlendirmesi. Dokuz Eylül Üniversitesi Tıp Dergisi 2012;26(1):21-6.
• 13. Carbone A, Roulland S, Gloghini A et al. Follicular lymphoma. Nat Rev Dis Prim- ers 2019;5(1):83.
• 14. Koiso H, Yokohama A, Mitsui T et al. Follicular lymphoma presenting with marked splenomegaly: Report of three cases. Acta Haematol 2012;128(1):47-52.
• 15. Relander T, Johnson NA, Farinha P et al. Prognostic factors in follicular lympho- ma. J Clin Oncol 2010;28(17):2902-13.
• 16. Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with ad- vanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106(12):3725-32.
• 17. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105(4):1417-23.
• 18. Flinn IW, van der Jagt R, Kahl BS et al. Randomized trial of bendamustine-ritux- imab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study. Blood 2014;123(19):2944-52.